Drug Combo Proves Powerful Against Lung Cancer Tonawanda NY

A two-drug combination treatment in Tonawanda proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Kelvin P Lee
(716) 845-2300
Elm And Carlton St
Buffalo, NY
JAMES THOMPSON, MD
(716) 845-2300
Elm And Carlton Street
Buffalo, NY
MICHAEL SNYDERMAN, MD
(716) 824-5588
515 Abbott Road
Buffalo, NY
Eunice Sue Wang, MD
716-845-3544
Elm and Carlton St
Buffalo, NY
Victor Ernesto Yosuic, MR
959 Indian Church Rd
West Seneca, NY
Cyrus Irani
(716) 845-2300
Elm And Carlton St
Buffalo, NY
Minsoo Kang
(716) 250-2000
3980 Sheridan Dr
Amherst, NY
STEVEN AMBRUSKO, MD
(412) 878-7349
219 Bryant Street
Buffalo, NY
GERALD LOGUE, MD
(716) 898-3941
462 Grider Street
Buffalo, NY
Bagirathan Janarthanam, MD
Roswell Park Cancer Center
Buffalo, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Lung Cancer Tonawanda NY
Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.
- Genetic Clues for Skin Cancer Therapies Tonawanda NY
- Exercise for Prostate Cancer Tonawanda NY
- Risks for Childhood Cancer Survivors Tonawanda NY
- Delayed Prostate Cancer Therapy Tonawanda NY
- Hormone Therapy for Breast Cancer Tonawanda NY
- Exercise for Breast Cancer Survival Tonawanda NY
- Fungal Infection Treatments Tonawanda NY
- Side Effect Of Chemotherapy Drugs Tonawanda NY